374 related articles for article (PubMed ID: 28880867)
1. Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: A randomized phase 1 study.
Molokie R; Lavelle D; Gowhari M; Pacini M; Krauz L; Hassan J; Ibanez V; Ruiz MA; Ng KP; Woost P; Radivoyevitch T; Pacelli D; Fada S; Rump M; Hsieh M; Tisdale JF; Jacobberger J; Phelps M; Engel JD; Saraf S; Hsu LL; Gordeuk V; DeSimone J; Saunthararajah Y
PLoS Med; 2017 Sep; 14(9):e1002382. PubMed ID: 28880867
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and pharmacodynamics of an oral formulation of decitabine and tetrahydrouridine.
Lau H; Woost PG; Friedrich U; Clausen WHO; Jacobberger JW; Saunthararajah Y
Eur J Haematol; 2023 Sep; 111(3):345-355. PubMed ID: 37417197
[TBL] [Abstract][Full Text] [Related]
3. Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabine.
Lavelle D; Vaitkus K; Ling Y; Ruiz MA; Mahfouz R; Ng KP; Negrotto S; Smith N; Terse P; Engelke KJ; Covey J; Chan KK; Desimone J; Saunthararajah Y
Blood; 2012 Feb; 119(5):1240-7. PubMed ID: 22160381
[TBL] [Abstract][Full Text] [Related]
4. Subchronic oral toxicity study of decitabine in combination with tetrahydrouridine in CD-1 mice.
Terse P; Engelke K; Chan K; Ling Y; Sharpnack D; Saunthararajah Y; Covey JM
Int J Toxicol; 2014; 33(2):75-85. PubMed ID: 24639139
[TBL] [Abstract][Full Text] [Related]
5. Effects of 5-aza-2'-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease.
Saunthararajah Y; Hillery CA; Lavelle D; Molokie R; Dorn L; Bressler L; Gavazova S; Chen YH; Hoffman R; DeSimone J
Blood; 2003 Dec; 102(12):3865-70. PubMed ID: 12907443
[TBL] [Abstract][Full Text] [Related]
6. Combined inhibition of histone deacetylase and cytidine deaminase improves epigenetic potency of decitabine in colorectal adenocarcinomas.
Tang Z; Liu L; Borlak J
Clin Epigenetics; 2023 May; 15(1):89. PubMed ID: 37208732
[TBL] [Abstract][Full Text] [Related]
7. A pilot clinical trial of oral tetrahydrouridine/decitabine for noncytotoxic epigenetic therapy of chemoresistant lymphoid malignancies.
Hill B; Jagadeesh D; Pohlman B; Dean R; Parameswaran N; Chen J; Radivoyevitch T; Morrison A; Fada S; Dever M; Robinson S; Lindner D; Smith M; Saunthararajah Y
Semin Hematol; 2021 Jan; 58(1):35-44. PubMed ID: 33509441
[TBL] [Abstract][Full Text] [Related]
8. Clinical studies with fetal hemoglobin-enhancing agents in sickle cell disease.
Saunthararajah Y; DeSimone J
Semin Hematol; 2004 Oct; 41(4 Suppl 6):11-6. PubMed ID: 15534852
[TBL] [Abstract][Full Text] [Related]
9. Maintenance of elevated fetal hemoglobin levels by decitabine during dose interval treatment of sickle cell anemia.
DeSimone J; Koshy M; Dorn L; Lavelle D; Bressler L; Molokie R; Talischy N
Blood; 2002 Jun; 99(11):3905-8. PubMed ID: 12010787
[TBL] [Abstract][Full Text] [Related]
10. 2-deoxy 5-azacytidine and fetal hemoglobin induction in sickle cell anemia.
Koshy M; Dorn L; Bressler L; Molokie R; Lavelle D; Talischy N; Hoffman R; van Overveld W; DeSimone J
Blood; 2000 Oct; 96(7):2379-84. PubMed ID: 11001887
[TBL] [Abstract][Full Text] [Related]
11. Tetrahydrouridine, cytidine analogues, and hemoglobin F.
DeSimone J; Heller P; Molokie RE; Hall L; Zwiers D
Am J Hematol; 1985 Mar; 18(3):283-8. PubMed ID: 2579548
[TBL] [Abstract][Full Text] [Related]
12. A pilot clinical trial of the cytidine deaminase inhibitor tetrahydrouridine combined with decitabine to target DNMT1 in advanced, chemorefractory pancreatic cancer.
Sohal D; Krishnamurthi S; Tohme R; Gu X; Lindner D; Landowski TH; Pink J; Radivoyevitch T; Fada S; Lee Z; Shepard D; Khorana A; Saunthararajah Y
Am J Cancer Res; 2020; 10(9):3047-3060. PubMed ID: 33042633
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic regulation by decitabine of melanoma differentiation in vitro and in vivo.
Alcazar O; Achberger S; Aldrich W; Hu Z; Negrotto S; Saunthararajah Y; Triozzi P
Int J Cancer; 2012 Jul; 131(1):18-29. PubMed ID: 21796622
[TBL] [Abstract][Full Text] [Related]
14. Induction of fetal hemoglobin in the treatment of sickle cell disease.
Fathallah H; Atweh GF
Hematology Am Soc Hematol Educ Program; 2006; ():58-62. PubMed ID: 17124041
[TBL] [Abstract][Full Text] [Related]
15.
Gilmartin AG; Groy A; Gore ER; Atkins C; Long ER; Montoute MN; Wu Z; Halsey W; McNulty DE; Ennulat D; Rueda L; Pappalardi M; Kruger RG; McCabe MT; Raoof A; Butlin R; Stowell A; Cockerill M; Waddell I; Ogilvie D; Luengo J; Jordan A; Benowitz AB
Haematologica; 2021 Jul; 106(7):1979-1987. PubMed ID: 32586904
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial of sequential low-dose 5-aza-2'-deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma.
Gollob JA; Sciambi CJ; Peterson BL; Richmond T; Thoreson M; Moran K; Dressman HK; Jelinek J; Issa JP
Clin Cancer Res; 2006 Aug; 12(15):4619-27. PubMed ID: 16899610
[TBL] [Abstract][Full Text] [Related]
17. 5-Azacytidine increases HbF production and reduces anemia in sickle cell disease: dose-response analysis of subcutaneous and oral dosage regimens.
Dover GJ; Charache S; Boyer SH; Vogelsang G; Moyer M
Blood; 1985 Sep; 66(3):527-32. PubMed ID: 2411310
[TBL] [Abstract][Full Text] [Related]
18. DNA hypo-methylating agents and sickle cell disease.
Saunthararajah Y; Lavelle D; DeSimone J
Br J Haematol; 2004 Sep; 126(5):629-36. PubMed ID: 15327513
[TBL] [Abstract][Full Text] [Related]
19. Plasma pharmacokinetics and oral bioavailability of 3,4,5,6-tetrahydrouridine, a cytidine deaminase inhibitor, in mice.
Beumer JH; Eiseman JL; Parise RA; Florian JA; Joseph E; D'Argenio DZ; Parker RS; Kay B; Covey JM; Egorin MJ
Cancer Chemother Pharmacol; 2008 Aug; 62(3):457-64. PubMed ID: 18008070
[TBL] [Abstract][Full Text] [Related]
20. Oral administration of the LSD1 inhibitor ORY-3001 increases fetal hemoglobin in sickle cell mice and baboons.
Rivers A; Vaitkus K; Jagadeeswaran R; Ruiz MA; Ibanez V; Ciceri F; Cavalcanti F; Molokie RE; Saunthararajah Y; Engel JD; DeSimone J; Lavelle D
Exp Hematol; 2018 Nov; 67():60-64.e2. PubMed ID: 30125603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
